XOMA Royalty

XOMA · NASDAQ

Price unavailable right now.

No price history for this range.

Latest news

  • Press releaseGlobe Newswire

    XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date

  • Press releasePRNewswire

    Are AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TMHC, CZR, XOMA, and RAMP

  • Press releasePRNewswire

    Are XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    Are SEM, XOMA, SLNO, KORE Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?

  • Press releaseBusiness Wire

    XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA

  • Press releasePRNewswire

    ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation

  • NewsVandana Singh

    Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million

  • Press releasePRNewswire

    Are OGN, RMAX, XOMA, REAX Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    Shareholder Alert: Ademi LLP investigates whether XOMA Royalty Corporation is obtaining a Fair Price for Public Shareholders

  • Press releaseBusiness Wire

    XOMA Stock Alert: Halper Sadeh LLC is Investigating Whether XOMA Royalty Corporation is Obtaining a Fair Price for its Shareholders

  • News

    Ligand Pharmaceuticals To Acquire XOMA Royalty For $39.00 Per Share In Cash, Ligand Raises FY2026 Adj. EPS Guidance To $8.50-9.50 And Expects The Transaction To Be Accretive By $1.50 Per Share To Adj. EPS In 2027

  • Press releaseGlobe Newswire

    Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator

  • Press releaseGlobe Newswire

    XOMA Royalty Declares Quarterly Preferred Stock Dividends

  • NewsDylan Berman

    XOMA Royalty Jumps After Q4 Double Beat, Signals Pipeline Catalysts Ahead

  • News

    Earnings Scheduled For March 18, 2026

  • News

    XOMA Q4 EPS $0.26 Beats $(0.15) Estimate, Sales $13.757M Beat $11.049M Estimate

  • Press releaseGlobe Newswire

    XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements

  • Press releaseGlobe Newswire

    XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

  • News

    What Analysts Are Saying About XOMA Royalty Stock

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

  • Press releaseGlobe Newswire

    XOMA Royalty Announces CFO Transition

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

  • Press releaseGlobe Newswire

    XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab

  • Press releaseGlobe Newswire

    XOMA Royalty Declares Quarterly Preferred Stock Dividends

  • Press releaseGlobe Newswire

    XOMA Royalty Enters into Agreement to Acquire Generation Bio

  • NewsVandana Singh

    Why Is XOMA Royalty Stock Sinking Thursday?

  • NewsAvi Kapoor

    Academy Sports and Outdoors, Tronox, STAAR Surgical And Other Big Stocks Moving Higher On Tuesday

  • Press releaseGlobe Newswire

    Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition

  • Press releaseGlobe Newswire

    XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

  • Press releaseGlobe Newswire

    Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty

  • Press releasePRNewswire

    ESSA Pharma Inc. Amends Agreement with XenoTherapeutics

  • Press releaseGlobe Newswire

    Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting

  • Press releaseGlobe Newswire

    XOMA Royalty Declares Quarterly Preferred Stock Dividends

  • Press releaseGlobe Newswire

    XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

  • Press releaseBusiness Wire

    HILLEVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX

  • Press releasePRNewswire

    ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HilleVax, Inc.

  • Press releaseGlobe Newswire

    XOMA Royalty Declares Quarterly Preferred Stock Dividends

  • News

    XOMA Royalty Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

  • Press releaseGlobe Newswire

    XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements

  • News

    The Analyst Verdict: XOMA Royalty In The Eyes Of 4 Experts

  • Press releaseGlobe Newswire

    XOMA Royalty Declares Quarterly Preferred Stock Dividends

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.